Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$3.82 -1.3%	$3.90	$2.60 ▼ $7.77	$216.86M	1.58	95,759 shs	62,810 shs
FENC Adherex Technologies	$7.84 -4.2%	$8.33	$3.96 ▼ $9.30	$217.40M	0.4	53,871 shs	54,838 shs
IFRX InflaRx	$0.86 -5.0%	$0.88	$0.71 ▼ $2.82	$57.73M	1.29	374,925 shs	123,610 shs
LRMR Larimar Therapeutics	$3.44 -0.6%	$2.99	$1.61 ▼ $9.50	$220.26M	0.93	1.12 million shs	1.16 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	0.00%	-4.98%	+1.33%	-12.39%	-19.41%
FENC Adherex Technologies	0.00%	-9.15%	-9.73%	+24.84%	+36.11%
IFRX InflaRx	0.00%	-4.31%	+6.83%	-47.88%	-41.50%
LRMR Larimar Therapeutics	0.00%	-11.34%	+9.55%	+27.88%	-57.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSGN Design Therapeutics	0.328 of 5 stars	1.0	1.0	0.0	2.5	0.6
FENC Adherex Technologies	1.8088 of 5 stars	3.6	1.0	0.6	3.3	0.0
IFRX InflaRx	3.1777 of 5 stars	3.5	5.0	2.3	1.7	0.6
LRMR Larimar Therapeutics	2.2193 of 5 stars	3.6	2.0	2.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.00	Hold	$4.00	4.71% Upside
FENC Adherex Technologies	3.25	Buy	$13.00	65.82% Upside
IFRX InflaRx	3.00	Buy	$6.60	667.44% Upside
LRMR Larimar Therapeutics	3.11	Buy	$18.50	437.79% Upside

Current Analyst Ratings Breakdown

Latest IFRX, FENC, DSGN, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
5/29/2025	IFRX InflaRx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$2.00
5/29/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $3.00
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/14/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00
5/8/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00

(Data available from 8/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.28 per share	N/A
FENC Adherex Technologies	$47.54M	4.57	$0.03 per share	242.76	($0.21) per share	-37.33
IFRX InflaRx	$180K	320.73	N/A	N/A	$1.13 per share	0.76
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$49.59M	-$0.99	N/A	N/A	N/A	N/A	-22.85%	-22.02%	8/4/2025 (Estimated)
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
IFRX InflaRx	-$49.85M	-$0.82	N/A	N/A	N/A	N/A	-64.17%	-53.39%	8/7/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/6/2025 (Estimated)

Latest IFRX, FENC, DSGN, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	FENC Adherex Technologies	-$0.06	N/A	N/A	N/A	$9.52 million	N/A
8/7/2025	Q2 2025	IFRX InflaRx	-$0.24	N/A	N/A	N/A	$0.02 million	N/A
8/6/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.4877	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q1 2025	DSGN Design Therapeutics	-$0.32	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/7/2025	Q1 2025	IFRX InflaRx	-$0.18	-$0.14	+$0.04	-$0.14	$0.03 million	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	28.37	28.37
FENC Adherex Technologies	N/A	5.13	4.97
IFRX InflaRx	N/A	5.28	4.86
LRMR Larimar Therapeutics	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
FENC Adherex Technologies	55.51%
IFRX InflaRx	42.39%
LRMR Larimar Therapeutics	91.92%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	31.20%
FENC Adherex Technologies	10.98%
IFRX InflaRx	16.30%
LRMR Larimar Therapeutics	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	40	56.77 million	39.06 million	Optionable
FENC Adherex Technologies	10	27.73 million	24.69 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable

IFRX, FENC, DSGN, and LRMR Headlines

Recent News About These Companies

Larimar Therapeutics (LRMR) Expected to Announce Earnings on Wednesday

1 hour ago | americanbankingnews.com

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

July 31, 2025 | globenewswire.com

Larimar Therapeutics shares drop following $60 million public offering

July 30, 2025 | msn.com

Larimar Therapeutics (LRMR) Expected to Announce Quarterly Earnings on Wednesday

July 30, 2025 | marketbeat.com

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

July 29, 2025 | globenewswire.com

Larimar Therapeutics, Inc. Announces Pricing of $60 Million Public Offering of Common Stock

July 29, 2025 | quiverquant.comQ

Larimar Therapeutics Announces Proposed Underwritten Public Offering

July 29, 2025 | globenewswire.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $18.50 Consensus PT from Brokerages

July 29, 2025 | americanbankingnews.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages

July 26, 2025 | marketbeat.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16, 2025 | zacks.com

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

July 8, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Larimar Therapeutics (LRMR)

June 24, 2025 | theglobeandmail.com

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

June 23, 2025 | globenewswire.com

Larimar Therapeutics to Host Conference Call on Regulatory Updates for Nomlabofusp Clinical Development Program

June 22, 2025 | nasdaq.com

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

June 20, 2025 | finance.yahoo.com

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

June 20, 2025 | globenewswire.com

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock

May 24, 2025 | investing.com

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential

May 21, 2025 | insidermonkey.com

Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 6.40%

May 6, 2025 | aaii.comA

Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss

May 4, 2025 | tipranks.com

Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development

May 4, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, FENC, DSGN, and LRMR Company Descriptions

Design Therapeutics NASDAQ:DSGN

$3.82 -0.05 (-1.29%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.82 +0.01 (+0.13%)

As of 08/1/2025 04:10 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Adherex Technologies NASDAQ:FENC

$7.84 -0.34 (-4.16%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$7.86 +0.02 (+0.26%)

As of 08/1/2025 04:34 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

InflaRx NASDAQ:IFRX

$0.86 -0.05 (-4.97%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.86 +0.00 (+0.12%)

As of 08/1/2025 04:15 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Larimar Therapeutics NASDAQ:LRMR

$3.44 -0.02 (-0.58%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.49 +0.05 (+1.45%)

As of 08/1/2025 07:38 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time